Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
Abstract Background There is no clear data on the optimal duration of treatment with anti-interleukin-1 drugs in colchicine-resistant familial Mediterranean fever patients, as well as on the dose interval. This study aimed to assess patients whose canakinumab dose interval was adjusted according to...
Guardat en:
| Autors principals: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2023-11-01
|
| Col·lecció: | Pediatric Rheumatology Online Journal |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s12969-023-00925-5 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|